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Summary  Tuberculosis  (TB)  is  a  signiﬁcant  contributor  to  mortality  in  HIV-infected
patients.  Concurrent  TB  infection  is  also  a  signiﬁcant  contributing  factor  to  maternal
mortality  in  human  immunodeﬁciency  virus  (HIV)-infected  pregnant  women.  Studies
addressing  the  outcomes  of  TB  and  HIV  co-infection  among  pregnant  women  are  gen-
erally  infrequent.  Although  limited,  the  records  maintained  by  the  Revised  National
Tuberculosis  Control  Programme  (RNTCP)  and  the  National  AIDS  Control  Programme
(NACP)  in  Karnataka  State,  Southern  India  provide  information  about  the  numbers
of  pregnant  women  who  are  co-infected  with  TB  and  HIV  and  their  pregnancy  out-
comes.  We  reviewed  the  data  and  conducted  this  study  to  understand  how  TB-HIV
co-infection  inﬂuences  the  outcomes  of  pregnancy  in  this  setting.
We  sought  to  determine  the  incidence  and  treatment  and  delivery  outcomes  of
TB-HIV  co-infected  pregnant  women  in  programmatic  settings  in  Karnataka  State  in
southern  India.
The  study  participants  were  all  the  HIV-infected  pregnant  women  who  were
screened  for  tuberculosis  under  the  NACP  from  2008  to  2012.  For  the  purposes  of
 staff  in  the  ﬁeld  gathered  the  data  regarding  on  treatmentthis  study,  the  program
and  delivery  outcomes  of  pregnant  women.
A  total  of  seventeen  pregnant  women  with  TB-HIV  co-infection  were  identiﬁed
among  3,165,729  pregnant  women  (for  an  incidence  of  5.4  per  million  pregnan-
cies).  The  median  age  of  these  pregnant  women  was  24  years,  and  majority  were
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primiparous  women  with  WHO  HIV  stage  III  disease  and  were  on  a  stavudine-based
ART  regimen.  The  maternal  mortality  rates  were  18%  before  delivery  and  24%  after
delivery.  The  abortion  rate  was  24%,  and  the  neonatal  mortality  rate  was  10%.  The
anti-tuberculosis  treatment  and  anti-retroviral  treatment  outcome  mortality  rates
were  30%  and  53%,  respectively.
Although  the  incidence  of  TB  among  the  HIV-infected  pregnant  women  was  marginally
less  than  that  among  the  non-HIV-infected  women,  the  delivery  outcomes  were  rela-
tively  poorer.  The  current  strategy  for  the  management  of  TB  among  the  HIV-positive
rgent  review.
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protocol at  a  place  close  to  the  patient’s  resi-
dence, and  treatment  is  supervised  by  a Directly
Observed Treatment  (DOT)  provider.  The  super-pregnant  women  needs  u
©  2015  King  Saud  Bin  Ab
Limited.  All  rights  reserv
Introduction
Globally,  tuberculosis  (TB)  remains  one  of  the  major
causes of  death  in  adults  living  with  HIV  [1]. Peo-
ple infected  with  HIV  are  at  high  risk  for  developing
active TB  either  due  to  the  reactivation  of  a latent
infection or  the  progression  of  newly  acquired
tubercle bacilli  infections.  Among  women  in  the
reproductive  age  group,  TB-HIV  co-infection  is  a
signiﬁcant  non-obstetric  cause  of  maternal  mortal-
ity primarily  in  resource-limited  countries  [2—6].
The exact  incidence  of  tuberculosis  in  pregnancy
is not  readily  available  but  is  expected  to  be  as
high as  in  the  general  population  [7].  In  regions  with
high prevalences  of  TB  and  HIV,  it  is  estimated  that
more than  300,000  pregnant  women  are  infected
with TB  and  HIV  [8]. If  left  untreated,  pregnant
women with  TB  can  exhibit  a  mortality  of  up  to  40%
[6,7].  Active  tuberculosis  disease  in  HIV-infected
pregnant women  increases  the  risk  of  maternal
mortality by  nearly  300%  [9]. Neonatal  mortality  is
considerably  high  among  TB-HIV  co-infected  women
compared  to  HIV-uninfected  pregnant  women  [10].
An audit  of  maternal  mortality  in  Johannesburg,
South Africa  revealed  that  70%  of  the  deaths  in
women  infected  with  HIV  were  HIV-related  rather
than due  to  obstetric  causes,  and  these  deaths  were
mainly due  to  TB  and  pneumonia  [11,12].
In India,  collaborative  activities  to  control  TB-
HIV have  been  implemented  jointly  by  the  Revised
National Tuberculosis  Control  Programme  (RNTCP)
and the  National  AIDS  Control  Programme  (NACP)
since 2006  [13]. Under  the  NACP,  all  pregnant
women are  counseled  and  screened  for  HIV  at  pre-
vention  of  parent  to  child  transmission  (PPTCT)
centers routinely.  Those  found  to  be  HIV-positive
are evaluated,  clinical  staged  based  on  World
Health Organization  (WHO)  criteria,  and  initiated
on anti-retroviral  treatment  (ART)  [14]. All  HIV-
positive  pregnant  women  are  also  screened  for
v
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tuberculosis  at the  nearest  microscopy  center,  and
hose diagnosed  with  TB  are  initiated  on  appro-
riate treatment  based  on  the  RNTCP  protocol
6]. The  RNTCP  program  routinely  collects  infor-
ation about  the  HIV  statuses  of  TB  patients;
owever, information  about  pregnancy  and  deliv-
ry outcomes  are  not  collected  under  in  routine
rogram settings.  In  contrast,  the  NACP  program
oes  capture  information  about  the  delivery  and
irth outcomes.  We  speculate  that  pregnant  TB-
IV patients  belong  to  a  special  category  and  duly
equire additional  services  for  adequate  manage-
ent.  We  conducted  this  study  under  programmatic
ettings because  there  is  limited  information
bout (a)  the  incidence  of  TB  among  HIV-infected
regnant women  and  (b)  their  delivery,  birth,
nti-tuberculosis  and  anti-retroviral  treatment  out-
omes in  the  study  settings.
ethods
his  study  involves  a  case  series  reported  from
he state  of  Karnataka,  India.  This  state  has  a
opulation  of  61  million  and  is  considered  to
ave a relatively  advanced  HIV  epidemic;  based
n the  HIV  Surveillance  Survey  (2010—2011)  data,
he HIV  prevalence  is  0.69%,  which  amounts  to
50,000  persons  living  with  HIV  [15]. The  NACP
elivers  its  services  through  nearly  1515  public  HIV-
esting sites  and  44  ART  centers.  All  HIV-positive
regnant women  infected  with  tuberculosis  are
nitiated  on  the  RNTCP-recommended  treatmentision and  monitoring  of TB  treatment  and  the
atient  response  to  treatment  is  also  monitored
y the  ART  center  physician.  All  pregnant  women
ested  for  HIV  from  the  1st  of  April  2008  to
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dB/HIV  co-infection  among  pregnant  women  
he  31st  of  March  2012  were  included  in  the
tudy.
ata collection
he  data  of  the  TB-  and  HIV-co-infected  patients
ere obtained  from  the  district  ART  centers.  Each
RT center  has  in  its  registers  a  list  of  HIV-infected
atient registrations  from  the  pre-ART  registry  (HIV
are), and  for  patients  who  are  eligible  for  ART,
he patient  details  are  recorded  in  the  ART  enroll-
ent register.  The  records  of  TB-HIV  co-infected
atients are  maintained  in  a  separate  TB/HIV  reg-
ster and  are  updated  regularly  by  designated  staff
t the  ART  center.  For  the  purposes  the  study,
ariables, such  as  age,  weight,  parity,  type  of
elivery,  birth  outcome,  WHO  clinical  staging,  type
f TB,  TB  treatment  outcome,  and  ART,  were
etrieved from  the  records  and  registers.  All  of
he relevant  information  was  recorded  in  a data
ollection form.  All  of  the  co-infected  pregnant
omen registered  in  the  ART  centers  were  fol-
owed up  on  a  monthly  basis  by  both  the  HIV
rogram staff  and  the  general  health  system  ﬁeld
taff. Detailed  follow-ups  ensured  that  the  deliver-
es were  performed  in  hospitals,  and  the  ART  center
taff maintained  detailed  reports  on  these  cases.
istrict-level  program  ofﬁcers  helped  to  track  and
rovide  details  about  these  cases.  A  few  oper-
tional deﬁnitions  were  considered  for  delivery
i.e., abortion:  the  loss  or  termination  of  pregnancy
efore 20  completed  weeks  of  gestation;  normal
elivery: delivery  through  normal  birth  canal  or
ithout  C-section;  and  C-section:  delivery  through
n incision  made  in  the  abdomen  and  uterine  cav-
ty); RNTCP  treatment  outcome  (i.e.,  cured:  an
nitially sputum  smear-positive  patient  who  com-
leted treatment  and  had  negative  sputum  smears
n two  occasions  one  of  which  was  at  the  end  of
reatment); and  NACP  treatment  outcome  (i.e.,
oss to  follow  up  (LFTU):  patients  who  did  not  come
o the  clinics  for  at  least  90  days  after  their  last
cheduled appointment)  [16—18].
ata analysis
he  data  from  the  data  collection  forms  were
ntered in  an  Excel  sheet,  and  the  continuous  vari-
bles were  analyzed  in  terms  of  the  medians  and
tandard deviations,  while  the  categorical  variables
ere analyzed  in  terms  of  proportions.thics
he  study  included  only  reviews  of  records  and
eports. Abstracted  data  were  anonymized  and
w
l
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ot  linked  to  any  personal  identiﬁers.  Appropri-
te administrative  approvals  were  obtained  from
ational  AIDS  Control  Organization  of  New  Delhi,
ndia.
esults
uring  the  study,  a total  of  3,165,729  pregnant
omen were  tested  for  HIV,  and  11,617  (0.36%)
ere found  to  be  HIV-positive.  A  total  of  17  HIV-
ositive  pregnant  women  with  TB  and  on  ART  and
nti-TB (ATT)  treatment  were  identiﬁed.  Thus,  the
ncidence  of  TB-HIV  co-infection  among  pregnant
omen  was  5.4  per  million  pregnant  women.
The proﬁles  of  seventeen  TB-HIV  co-infected
regnant women  are  displayed  in  Table  1. The  age
ange was  19—30  years.  The  median  age  of  the
omen was  24  years  (standard  deviation:  3.28),
nd the  majority  (65%)  were  in  WHO  clinical  stage
II. Of  those  seventeen  TB-HIV  co-infected  women,
ight  (47%)  were  pregnant  for  the  ﬁrst  time,  and
he remaining  nine  were  pregnant  for  second  or
ore times.  Ten  (58%)  patients  delivered,  four
24%) aborted,  and  three  (18%)  died  before  deliv-
ry. Among  the  ten  delivered  neonates,  nine  (90%)
ere alive,  and  one  had  died.  The  proportions  of
mear-positive  pulmonary  TB,  extra-pulmonary  TB
nd smear-negative  pulmonary  TB  were  53%,  30%
nd 17%,  respectively.  Among  the  14  patients  who
ompleted  treatment,  six  (43%)  had  successful  TB
reatment  outcomes,  ﬁve  (36%)  died,  and  three
21%) were  lost  to  follow-up  for  TB  treatment.  At
he end  of  the  study  period,  among  the  seven-
een women  on  ART,  only  seven  (41%)  were  alive
nd on  ART;  seven  (41%)  had  died,  and  three  (18%)
ere lost  to  follow-up.  The  pregnant  women  with
oor delivery  outcomes  had  signiﬁcantly  lower  ini-
ial weights  and  lived  greater  distances  from  the
earest health  facility.
iscussion
lthough  TB-HIV  co-infection  has  been  extensively
tudied, this  is  the  ﬁrst  study  to  examine  the  inci-
ence of  TB-HIV  co-infection  in  pregnant  women
nd their  delivery  outcomes  in  India.  The  incidence
f TB  among  HIV-infected  pregnant  women  was
ound to  be  5.4  per  million  pregnant  women.  The
elivery outcomes  of  these  co-infected  patients
ere poor  overall.  The  study  ﬁndings  have  the  fol-
owing programmatic  implications.
First, only  59%  of  the  pregnant  women  with
B-HIV co-infection  had  successful  deliveries.
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Table  1  Proﬁles  of  seventeen  TB-HIV  co-infected  pregnant  women  in  Karnataka  in,2008—2012.
Age  Weight  at
registration
WHO
stage
CD4  count
at
registration
Gravida  Type  of  TB  Type  of
anti-TB
treatment
Type  of
anti-retroviral
treatment
Type  of
delivery
Outcome  of
baby  on
delivery
TB  treatment
outcome
ART  treatment
outcome
26  55  3  222  2  Smear-negative
pulmonary  TB
Cat 1 Stavudine-based  Normal
delivery
Alive  Treatment
Completed
Alive  on  ART
24  43  3  259  3  Extra  pulmonary Cat  1 Stavudine-based  Normal
delivery
Alive  Defaulted  LTFU
25  44  4  89  3  Extra  pulmonary Private  NA  Cesarean
section
Alive  Defaulted  Died
25  44  2  356  1  Smear-positive
pulmonary  TB
Cat 1  Zidovudine-
based
Abortion  Abortion  Defaulted  Alive  on  ART
19  48  3  248  1  Smear-positive
pulmonary  TB
Cat 2  Stavudine-based  Normal
delivery
Died  Cured  Alive  on  ART
30  48  3  94  3  Extra  pulmonary  Cat  1  Stavudine-based  Normal
delivery
Alive  On  treatment  Alive  on  ART
25  40  3  224  1  Smear-negative
pulmonary  TB
Cat 1  Zidovudine-
based
Nil  NA  Death  Died
20  49  3  274  1  Smear-positive
pulmonary  TB
Cat 1  Stavudine-based  Normal
delivery
Alive  Cured  Died
20  44  3  152  2  Smear-positive
pulmonary  TB
Cat 1  Stavudine-based  Normal
delivery
Alive  Treatment
Completed
Alive  on  ART
27  48  2  312  1  Extra  pulmonary  Cat  1  NA  Nil  NA  Death  Died
22  40  4  283  2  Smear-positive
pulmonary  TB
Cat 1  Zidovudine-
based
Normal
delivery
Alive  Cured  Alive  on  ART
22  40  3  34  2  Smear-positive
pulmonary  TB
Cat 1  Stavudine-based  Nil  NA  Death  Died
20  40  3  928  1  Smear-positive
pulmonary  TB
Cat 1  Stavudine-based  Abortion  Abortion  Treatment
Completed
Alive  on  ART
30  50  3  168  2  Smear-negative
pulmonary  TB
Cat 1  Zidovudine-
based
Normal
delivery
Alive  On  treatment  Alive  on  ART
22  22  3  48  4  Smear-positive
pulmonary  TB
Cat 1  Stavudine-based  Abortion  Abortion  Death  Died
24  50  4  187  1  Extra  pulmonary  Cat  1  Zidovudine-
based
Abortion  Abortion  On  treatment  Alive  on  ART
24  37  4  111  1  Smear-positive
pulmonary  TB
Cat 1  Zidovudine-
based
Normal
delivery
Alive  Death  Died
NA, not applicable; LTFU, lost to follow-up.
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RB/HIV  co-infection  among  pregnant  women  
hree  (18%)  of  patients  died  before  delivery,
nd four  (24%)  had  abortions.  Previous  studies
n low-resource  high-HIV  prevalence  settings  have
lso demonstrated  signiﬁcant  maternal  morbidity
nd mortality  in  pregnant  women  with  TB-HIV
o-infection [11,12,19,20]. Among  the  delivered
nfants, 90%  were  alive,  and  this  result  is  similar  to
hat of  another  study  in  a  resource-poor  setting  in
igeria [21].  The  diagnosis  of  tuberculosis  among
regnant  women  is  a  challenge  in  programmatic
ettings. These  unique  situations  call  for  action
egarding  the  use  of  innovative  diagnostic  algo-
ithm,  screening  tools  and  linkages  with  maternity
ervices. Improved  patient  education,  counseling
nd follow-up  are  needed.
Second,  the  TB  treatment  outcomes  involved  a
3% success  rate  and  a  30%  death  rate,  which  is  wor-
isome.  The  RNTCP  records  indicated  a  79%  success
ate among  non-pregnant  TB-HIV-infected  patients
22].  TB  treatment  outcomes  among  pregnant
omen have  been  reported  to  be  as  good  as  those
n non-pregnant  women.  TB  treatment  consists
f ﬁrst-line  anti-TB  drugs  (isoniazid,  rifampicin,
yrazinamide  and  ethambutol)  given  on  alternate
ays [23].  We  did  not  come  across  any  study  that
eported  TB  treatment  outcomes  among  pregnant
omen with  TB-HIV  co-infections.  Further  studies
re needed  to  evaluate  the  causes  of  poor  TB  treat-
ent outcomes  in  this  vulnerable  group.
Third,  while  nearly  53%  of  the  patients  were  alive
nd continuing  their  ART,  the  remaining  patients
ere either  lost  to  follow  up  or  had  died.  The
utcomes among  only  HIV-infected,  on-ART  women
ndicated  that  71%  of  the  patients  were  alive  and  on
RT treatment  after  two  years  [24].  In  the  present
tudy, a  mortality  as  high  as  41%  was  found  among
regnant  women  with  TB-HIV  co-infection,  which
arrants  further  studies  to  identify  the  reasons  for
his high  mortality.
Finally,  the  entire  approach  of  the  use  of  the  cur-
ent strategy  for  detecting  and  treating  TB  among
IV-infected  pregnant  women  requires  urgent  eval-
ation in  our  opinion.  Moreover,  there  is  a  need  to
apture  these  data  both  in  HIV  and  TB  programs  to
mprove  better  coordination  and  further  planning.
ubstantial efforts  should  be  made  by  the  Repro-
uctive and  Child  Health  Programme  to  routinely
creen pregnant  women  for  tuberculosis  [25].
The strength  of  this  study  is  that  large  numbers
f pregnant  HIV  patients  were  screened  for  tuber-
ulosis under  routine  program  settings  and  likely
rovided  an  acceptable  estimate  of  the  HIV-TB  co-
nfection  rate  among  pregnant  women.  This  study
lso highlighted  the  poor  maternal  and  fetal  out-
omes associated  with  TB-HIV  co-infection  during
regnancy.  A  major  limitation  of  this  study  is  that
[
[469
t was  primarily  a  review  of the  registers  of  the  ART
enters  and  is  thus  limited  by  a lack  of  complete
nformation,  e.g.,  detailed  clinical  maternal-fetal
utcome reports.  Moreover,  the  number  of  patients
as small,  and  possible  confounders,  such  as  the
linical and  socio-economic  characteristics  of  the
atients,  were  not  included  because  we  primarily
elied on  data  from  program  records  and  reports.
In conclusion,  pregnant  TB/HIV  co-infected
atients constitute  a  high-risk  and  vulnerable  group
ith extremely  poor  maternal  and  fetal  outcomes.
pecial attention  should  focused  on  the  group  by
he national  program  for  better  management  and
inkage with  quality  medical  and  maternity  care.
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